Literature DB >> 22388331

Synthetic cathinones (bath salts): legal status and patterns of abuse.

Jennifer A Fass1, Andrea D Fass, Angela S Garcia.   

Abstract

OBJECTIVE: To review the current legal status and patterns of abuse of bath salts. DATA SOURCES: A literature search was conducted through MEDLINE (1950-December 2011), PubMed (1966-December 2011), EMBASE (1966-December 2011), and International Pharmaceutical Abstracts (1970-December 2011) using the search terms bath salts, mephedrone, and methylenedioxypyrovalerone to identify articles on the legal status of bath salts and on studies focusing on patterns of abuse of bath salts. The GovTrack.us Web site was searched to determine the status of federal bills regarding bath salts. The National Association of Boards of Pharmacy and Drug Enforcement Administration Web sites and the Federal Register were also examined to identify legislation on bath salts. STUDY SELECTION AND DATA EXTRACTION: Case reports and studies regarding bath salts were examined. Federal laws involving bath salts were also evaluated. DATA SYNTHESIS: The Department of Justice issued a final order in the Federal Register, temporarily placing the 3 synthetic stimulants, mephedrone, methylenedioxypyrovalerone, and methylone, under Schedule I of the Controlled Substances Act. Literature evaluated included case reports, retrospective studies, surveys, toxicology data, and chemical analyses studies. Information in the literature demonstrated that bath salts are highly abused, and common adverse effects include hypertension, tachycardia, and psychiatric symptoms.
CONCLUSIONS: Psychoactive substances recently sold as bath salts have been placed in Schedule I of the Controlled Substances Act. Pharmacists can play an important role in raising awareness on the dangers of bath salts abuse through patient counseling and community outreach programs. The evidence on legal status and patterns of abuse clearly demonstrates that bath salts contain dangerous substances that should be permanently controlled.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388331     DOI: 10.1345/aph.1Q628

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  18 in total

1.  Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine.

Authors:  J Elliott Robinson; Abigail E Agoglia; Eric W Fish; Michael C Krouse; C J Malanga
Journal:  Behav Brain Res       Date:  2012-06-21       Impact factor: 3.332

Review 2.  Drug use as a driver of HIV risks: re-emerging and emerging issues.

Authors:  Nabila El-Bassel; Stacey A Shaw; Anindita Dasgupta; Steffanie A Strathdee
Journal:  Curr Opin HIV AIDS       Date:  2014-03       Impact factor: 4.283

3.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

Review 4.  Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.

Authors:  Vikas Khullar; Ankur Jain; Maryam Sattari
Journal:  J Gen Intern Med       Date:  2014-02-20       Impact factor: 5.128

5.  Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

Authors:  Ryan Vandrey; Matthew W Johnson; Patrick S Johnson; Miral A Khalil
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2013-04

6.  Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication.

Authors:  Justin L Poklis; Carol R Nanco; Michelle M Troendle; Carl E Wolf; Alphonse Poklis
Journal:  Drug Test Anal       Date:  2013-09-02       Impact factor: 3.345

7.  Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.

Authors:  Justin L Poklis; Kelly G Devers; Elise F Arbefeville; Julia M Pearson; Eric Houston; Alphonse Poklis
Journal:  Forensic Sci Int       Date:  2013-10-18       Impact factor: 2.395

8.  A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug.

Authors:  S Rutherfoord Rose; Justin L Poklis; Alphonse Poklis
Journal:  Clin Toxicol (Phila)       Date:  2013-03       Impact factor: 4.467

9.  Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Catherine E Sykes; Mrudang M Shah; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2013-01-08       Impact factor: 5.372

10.  Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Nieves Herrera-Mundo; Dina M Francescutti; Donald M Kuhn
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.